PART I OVERVIEW We are a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. We acquire rights to products and product candidates by licensing or otherwise acquiring an ownership interes...
Q2 FY2026 — expected 2026-09-16
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | DERM | discussed_in_filing Cybersecurity | |
| topic_mention | DERM | discussed_in_filing Trusted Computing | |
| topic_mention | DERM | discussed_in_filing Blockchain & Crypto | |
| topic_mention | DERM | discussed_in_filing Regulation | |
| topic_mention | DERM | discussed_in_filing Healthcare & Bio | |
| topic_mention | DERM | discussed_in_filing Platform & Ecosystem | |
| topic_mention | DERM | discussed_in_filing Sovereign & Government | |
| topic_mention | DERM | discussed_in_filing Cybersecurity | |
| topic_mention | DERM | discussed_in_filing Trusted Computing | |
| topic_mention | DERM | discussed_in_filing Blockchain & Crypto | |
| topic_mention | DERM | discussed_in_filing Regulation | |
| topic_mention | DERM | discussed_in_filing Healthcare & Bio | |
| topic_mention | DERM | discussed_in_filing Platform & Ecosystem | |
| topic_mention | DERM | discussed_in_filing Sovereign & Government | |
| topic_mention | DERM | discussed_in_filing Cybersecurity | |
| topic_mention | DERM | discussed_in_filing Trusted Computing | |
| topic_mention | DERM | discussed_in_filing Blockchain & Crypto | |
| topic_mention | DERM | discussed_in_filing Regulation | |
| topic_mention | DERM | discussed_in_filing Healthcare & Bio | |
| topic_mention | DERM | discussed_in_filing Platform & Ecosystem |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001104659-26-034629 | EDGAR | 69K words |
| 2025-03-27 | 2024-12-31 | 0001410578-25-000490 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0001410578-24-000347 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001410578-23-000485 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0001410578-22-000558 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001104659-25-110457 | EDGAR | 22K words |
| 2025-08-12 | 2025-06-30 | 0001410578-25-001703 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001410578-25-001296 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001410578-24-001877 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001410578-24-001326 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001410578-24-000817 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001410578-23-002335 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001410578-23-001702 | EDGAR | — |
| 2023-05-22 | 2023-03-31 | 0001410578-23-001327 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001410578-22-003162 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001410578-22-002183 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001410578-22-001266 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-25 | 0001104659-26-034506 | EDGAR | 4K words |
| 2025-11-12 | 0001104659-25-110344 | EDGAR | — |
| 2025-09-26 | 0001104659-25-093891 | EDGAR | — |
| 2025-08-28 | 0001104659-25-084879 | EDGAR | — |
| 2025-08-12 | 0001104659-25-076825 | EDGAR | — |
| 2025-07-14 | 0001104659-25-067767 | EDGAR | — |
| 2025-06-26 | 0001104659-25-063032 | EDGAR | — |
| 2025-06-24 | 0001104659-25-061956 | EDGAR | — |
| 2025-05-14 | 0001104659-25-048502 | EDGAR | — |
| 2025-04-03 | 0001104659-25-031463 | EDGAR | — |
74 total filings indexed. 47 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001867066 |
| Ticker | DERM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report